江汉大学学报(自然科学版) ›› 2014, Vol. 42 ›› Issue (2): 64-69.

• 医学 • 上一篇    下一篇

Sorafenib 联合重组人可溶性TRAIL 蛋白对K562细胞增殖抑制和凋亡诱导的研究

王阿慧,凌艳英,庄秋容,邓家德   

  1. 广州医科大学 附属广州市第一人民医院检验科血液室,广东 广州 510180
  • 出版日期:2014-04-25 发布日期:2014-05-15
  • 作者简介:王阿慧(1980—),女,主治医师,硕士,研究方向:血液病及肿瘤的生物治疗。
  • 基金资助:
    广州市医药卫生科技项目(20131A011013)

Sorafenib Combined with Recombinant Human TRAIL on Growth Inhibition Effects and Inducing Apoptosis of Leukemia Cells of K562

WANG Ahui,LING Yanying,ZHUANG Qiurong,DENG Jiade   

  1. Department of Laboratory,Guangzhou First People′s Hospital , Guangzhou Medical University,Guangzhou 510180,Guangdong,China
  • Online:2014-04-25 Published:2014-05-15

摘要: 目的 观察比较联合应用重组人可溶性TRAIL蛋白及Sorafenib于人慢性髓系白血病细胞株K562与单独应用时细胞增殖抑制及诱导凋亡的差异。方法 通过CCK-8法检测两者对K562细胞的增殖抑制作用;Western-Blot 分析TRAIL 或与Sorafenib 联用对K562 细胞的凋亡诱导作用。结果 Sorafenib 与TRAIL 联合作用于K562 细胞时,其细胞的增殖抑制率及凋亡率均显著高于二者单独应用。结论 Sorafenib与TRAIL对K562细胞的增殖抑制及凋亡诱导有增敏及协同作用。

关键词: 索拉非尼, TRAIL, 白血病细胞, 细胞增殖抑制, 细胞凋亡

Abstract: Objective To investigate the different effect of Sorafenib and TRAIL on proliferation inhibition and apoptosis inducing of K562 cells. Methods Inhibition of K562 cells proliferation by Sorafenib alone and combined with TRAIL were studied in vitro using CCK-8. Apoptosis inducing rate of K562 cells by Sorafenib alone and combined with TRAIL were accessed by Western-Blot detection. Results Combination with Sorafenib and TRAIL synergistically increased the growth inhibition effects and enhanced the apoptosis rate of K562 cells. Conclusion Combination treatment of Sorafenib and TRAIL showed a synergistic anti-proliferative effect in K562 cells.

Key words: Sorafenib, TRAIL, leukemia cells of K562, proliferation inhibition, cell apoptosis

中图分类号: